Back to Search
Start Over
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis
- Source :
- Biology of Blood and Marrow Transplantation (Science Direct); 20240101, Issue: Preprints
- Publication Year :
- 2024
-
Abstract
- •Letermovir is effective in reducing clinically significant cytomegalovirus (CMV) infection in haploidentical or mismatched adult unrelated donor allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide-based graft-versus host-disease prophylaxis (letermovir, 21.9% versus no letermovir, 68.8%; P< .001).•Persistent CMV infection necessitating >28 days of therapy was more common in patients who did not receive letermovir (31.2% versus 6.2%; P = .02).•Late clinically significant CMV infection is rare if letermovir prophylaxis is continued beyond 14 weeks (1 of 24 patients; 4.2%).
Details
- Language :
- English
- ISSN :
- 10838791 and 15236536
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Biology of Blood and Marrow Transplantation (Science Direct)
- Publication Type :
- Periodical
- Accession number :
- ejs54611951
- Full Text :
- https://doi.org/10.1016/j.bbmt.2020.10.009